AzTrials
AzTrials

Barrett EsophagusCellSheet2NCT02455648

Autologous Cell Sheets Transplantation After ESD in the Esophagus

A study testing ESD/EMR plus Cell Sheet and ESD/EMR in people with Barrett Esophagus, run by Matthias Löhr at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Healing of mucosal defects after endoscopic mucosal resection in the oesophagus is prone to result in varying degrees of stenosis, especially if the resected area is large and/or circumferential. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Barrett Esophagus
What is being tested?
ESD/EMR plus Cell Sheet and ESD/EMR
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
10 participants
Where
1 siteSweden
Study dates
Jan 2012to 25 Mar 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Barrets esophagus, histologically confirmed, or early oesophageal cancer (both squamous and adeno)

Who cannot join

  • no consent can be given
  • prior ESD/EMR

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Gastrocentrum, KarolinskaUniversity Hospital

    Stockholm, 14186

Other trials in Sweden

About this study

Official title: Transplantation of Autologous Cell Sheets After Endoscopic Submucosal Dissection (ESD) for Early Adenocarcinoma of the Esophagus

Healing of mucosal defects after endoscopic mucosal resection in the oesophagus is prone to result in varying degrees of stenosis, especially if the resected area is large and/or circumferential. A new technique was described where autologous cells from the patients own oral mucosa are harvested and cultures on proprietary membranes (coated, temperature sensitive). These membranes, coined cell sheets, are used to cover the mucosal defects.

Read the detailed description

Aim Our aim is to evaluate if mucosal wound healing after endoscopic resection of early cancers or pre-cancerous lesions in the esophagus can be enhanced by transplantation of autologous cell sheets, thus reducing the risk of esophageal stenosis.

Background Adenocarcinoma and Barrett's esophagus The incidence of esophageal adenocarcinoma (EAC) has increased rapidly in the western world during the last decades. The reason for this increase is unknown, however, there is a strong association between the risk of developing EAC and gastro esophageal reflux. Chronic reflux may lead to Barrett's esophagus (BE), a condition where the squamous epithelium of the esophagus is replaced by columnar epithelium(1). BE is a premalignant condition with a lifetime risk of progressing to EAC of 5% in men and 3% in women (2).

The rate of progression is dependent on the grade of dysplasia in BE. One meta-analysis showed that low-grade dysplasia had a cancer incidence of 17/1,000 patient-years while high-grade dysplasia had an incidence of 66/1,000 patient-years (3). Medical treatment can reduce reflux symptoms, but there is no proof that it can decrease the risk of progression.

Treatment High-grade dysplasia The American Gastroenterological Association guidelines recommend that patients with high-grade dysplasia should be treated with surgical resection, endoscopic therapy or be offered surveillance with endoscopy every 3 months (4).

The Japanese Society for Gastrointestinal Endoscopy (JGSE) has described that endoscopic mucosal resection (EMR) is suitable for BE with high-grade dysplasia given that the diameter is ≤2 cm, < 1/3 of the esophageal circumference and limited to the mucosa. One of several advantages with EMR is that the resected mucosa can be examined histologically, compared to ablative therapies. Briefly, EMR is performed by submucosal injection to separate esophageal wall layers and then resection of the mucosa with a snare. A similar technique is endoscopic submucosal dissection (ESD) which also includes a submucosal injection, but instead of using a snare for resecting, the lesion is dissected with cutting instruments, such as the insulation-tipped (IT) knife.

Another approach is radiofrequency ablation using a cylindrical balloon with electrodes attached. One study showed complete eradication in 81.0% of high-grade dysplasia patients. Using ablation techniques, no tissue-samples are possible to collect for histology and there might also be a risk for buried Barrett's metaplasia or dysplasia which can progress. Complications to radiofrequency ablation include chest pain, upper gastrointestinal bleeding and stenosis formation (4). Moreover, patients undergoing ablation therapy require life-long surveillance endoscopy (5).

Early esophageal cancer The best curative treatment for early adenocarcinoma of the esophagus is considered to be esophagectomy with extended lymphadenectomy (3). Esophagectomy is an extensive surgical procedure with a mortality rate ranging between 4.9- 18.0% and risk for serious post-operative complications ranging between 26-41% (6). There are also frequently occurring post-operative complaints such as reflux, diarrhea and dysphagia (3).

Endoscopic therapy modalities that initially were reserved for patients with HGD have been used as alternatives to open surgery for early esophageal cancer. Although the practice was pioneered in Asia, it is increasingly practiced in Europe and the US (7). Early cancers classified as M1 (limited to epithelial layer) and M2 (invading lamina propria) may be good candidates for endoscopic therapy as they are not associated with lymph node metastasis (4). Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are the two resective techniques for removing mucosal tissue from the esophagus (8).

EMR, during which resection of the mucosa is performed with a snare after separation of the mucosa and the muscularis propria by submucosal injection of saline or hyaloronic acid injection is reserved for lesions < 15 mm in diameter (8). Larger lesions can be removed by so called piece meal resection, but the risk for an incomplete resection and subsequent local recurrence is substantial (9).

With ESD, where a submucosal dissection is performed after lifting and delineation of the lesion with a full-thickness mucosal circumferential cut much larger lesions can be removed en bloc, reducing the risk for an incomplete resection (8, 9).

Complications to EMR and ESD A common complication after both EMR and ESD is stenosis of the esophagus that can result in dysphagia. Mucosal defects larger than ¾ of the esophageal circumference are strongly associated with the development of stenosis. This can be treated by repetitive balloon dilatations. Takahashi et al retrospectively analyzed 437 patients treated with EMR/ESD. 90 patients had mucosal defects > ¾ of the esophageal circumference, of which 70 developed strictures requiring dilatation (1-45 dilatations per patient with a dilatation treatment time of 1-51 months). During dilatation therapy 7 perforations and 1 bleeding occurred (9).

Cell sheet transplantation In 2006, Ohki et al published an article on how to prevent inflammation after aggressive endoscopic resection. Scarring and stenosis of esophagus is caused by severe inflammation. In a canine model they tried to improve wound healing and reduce constriction. They created transplantable cell sheets from autologous oral mucosal epithelial cells (OMEC). In six animals esophageal ulcers were created by ESD. In three of the animals, two cell sheets were transplanted. Neither of the groups showed stricture, probably owing to the thicker muscle layer in dogs. However, the study showed that the transplant group had an enhanced wound healing with less inflammation. The results imply that cell sheet transplantation could potentially prevent stenosis after extensive mucosal resections. The cells did not cover the whole ulcer, but secretion of growth factors and cytokines are believed to have accelerated healing from native tissue. The harvested cell sheets still had intact extra cellular matrix which may act as glue to the tissue, making sutures unnecessary (10).

With the background of the above mentioned study Ohki et al have performed a feasibility study in humans (unpublished data), that thus far has shown very promising results (by direct communication with Dr Ohki).

Project description Study design Part 1 A feasibility study in patients with early adenocarcinoma or HGD in Barrett's mucosa where endoscopic resection is clinically indicated.

Part 2 A randomized controlled trial comparing ESD/EMR without cell sheet transplantation and ESD/EMR with cell sheet transplantation with respect to mucosal wound healing time and stricture formation .

Endpoints

  1. Primary endpoint: time to complete wound healing
  2. Secondary endpoints: esophageal stricture occurrence, inflammatory response measured with CellVizio, quality of life questionnaire (QLQ-OES18) Patients Inclusion criteria: Patients with intramucosal adenocarcinoma or high grade dysplasia in Barrett's esophagus where endoscopic resection is indicated in accordance with clinical guidelines.

Exclusion criteria:

Inability to give informed consent due to mental disorder, language barrier etc.

Power calculation:

Study part 1: The feasibility study in Western patients with adenocarcinoma, 10 patients will be recruited. No formal power calculation is made for the feasibility study.

Study part 2: Based on the results of the Japanese feasibility study wound healing was x % more rapid among cell sheet transplanted patients compared to expected healing time without transplantation. Assuming a difference of healing time of 30%, based on these Japanese data 12 patients would be required in each group to obtain a power of 80% with alpha= 0.05.

Preparation and transplantation of cell sheets Isolation and culturing of oral mucosal epithelial cells (OMEC) The patients' oral cavity will be sterilized with iodine (??) and local anesthesia will be administered to the inside of cheek. A 5 mm punch biopsy will be taken and the wound sutured. The biopsy will be treated with dispase to separate the epithelial cells, and after that they will be exposed to trypsin to create a single-cell suspension. The single-cell suspension will be seeded to temperature-responsive cell dish inserts and cultured for two weeks. No animal or bacterial derived material will be used for the culturing.

Harvesting of cell sheets When the endoscopists approximate that there is 40 minutes left of the ESD the investigators will put the dishes in a 20°C incubator for 30 minutes. The cell sheets will be transferred to a support membrane and transplanted to the esophageal ulcer by endoscopic forceps. A light pressure will be applied to improve attachment. Depending on the size of the ulcer, several cell sheets will be transplanted in the described manner.

Follow-up Weekly gastroscopies with Cellvizio. Weekly blood samples - (CRP, interleukins, Blood status) Quality of Life questionnaire (EORTC C30 and OES18)

Outcome measures:

  1. Healing will be measured endoscopically by visualising and photo-documenting a completely intact mucosa during the weekly gastroscopies. Along with these endoscopical pictures, a grading of healing based on confocal laser endomicroscopy (pCLE) will be developed, as the pilot study (first part of the study) demonstrated feasibility.
  2. Post-operative stenosis will be assessed by the easy passage of a standard 9 mm endoscope through the area of resection at weeks 1-4 and then in three-monthly intervals. Additionally, standard questionnaires will be used. Dysphagia is part of the EORTC OES18 module.

Relevance The investigators are hoping that this study will help us identify a method of preventing stenosis of esophagus after EMR/ESD. The stenosis commonly causes dysphagia that not only seriously reduces the quality of life but also could pose a threat for malnourishment.

Being tested
ESD/EMR plus Cell Sheet, ESD/EMR
Medical subject headings
Barrett Esophagus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ESD/EMR plus Cell SheetProcedure or surgery

    Patients receive ESD/EMR plus CellSheet:

    Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane ("Cell Sheet") that are inserted 2 weeks later on the occasion of the ESD or EMR

  • ESD/EMRProcedure or surgery

    only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane ("Cell Sheet") but NOT used for insertion in the patient during/after ESD/EMR two weeks later

Study groups in NCT02455648
Study groupRoleWhat they receive
ESD/EMR plus Cell SheetExperimentalPatients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
Receives: Procedure: ESD/EMR plus Cell Sheet
ESD/EMRSham comparatorpatients receive both mucosal biopsy but no placement of cell sheets during/after ESD
Receives: Procedure: ESD/EMR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-operative stenosis

    Development of an oesophageal stenosis that cannot be passed by a standard 9 mm endoscope

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 May 2015 (estimated)
  2. Study startJan 2012
  3. Primary completion25 Mar 2018
  4. Study completion25 Mar 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Model description
Single assignment
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02455648
Sponsor's protocol ID
232100-0016_24:2011/517374
Acronym
CellSheet2
Status last verified
Oct 2023
First submitted
20 May 2015
Last updated
24 Oct 2023
Results posted
No
Data monitoring committee
No

Publications

  • Jonas E, Sjoqvist S, Elbe P, Kanai N, Enger J, Haas SL, Mohkles-Barakat A, Okano T, Takagi R, Ohki T, Yamamoto M, Kondo M, Markland K, Lim ML, Yamato M, Nilsson M, Permert J, Blomberg P, Lohr JM. Transplantation of tissue-engineered cell sheets for stricture prevention after endoscopic submucosal dissection of the oesophagus. United European Gastroenterol J. 2016 Dec;4(6):741-753. doi: 10.1177/2050640616631205. Epub 2016 Feb 19.

    PubMed 28408991

Questions about this trial

What is this clinical trial studying?

A study testing ESD/EMR plus Cell Sheet and ESD/EMR in people with Barrett Esophagus, run by Matthias Löhr at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-operative stenosis (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02455648, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in